- South Korea
- /
- Pharma
- /
- KOSE:A003850
Discover These 3 Undiscovered Gems in South Korea with Strong Financials
Reviewed by Simply Wall St
The South Korea stock market has experienced recent volatility, with the KOSPI index seeing fluctuations and mixed performances across various sectors. As investors navigate these uncertain times, identifying stocks with strong financials becomes crucial for long-term success. In this article, we will explore three undiscovered gems in South Korea that exhibit robust financial health and potential for growth amidst the current market dynamics.
Top 10 Undiscovered Gems With Strong Fundamentals In South Korea
Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
---|---|---|---|---|
Korea Airport ServiceLtd | NA | 3.97% | 42.22% | ★★★★★★ |
Korea Cast Iron Pipe Ind | NA | 1.97% | 8.84% | ★★★★★★ |
Korea Ratings | NA | 1.13% | 0.54% | ★★★★★★ |
Samyang | 49.49% | 6.68% | 23.96% | ★★★★★★ |
Woori Technology Investment | NA | 22.60% | -1.67% | ★★★★★★ |
iMarketKorea | 28.53% | 5.35% | 1.30% | ★★★★★☆ |
ASIA Holdings | 34.98% | 8.43% | 16.17% | ★★★★★☆ |
Daewon Cable | 30.50% | 8.72% | 60.38% | ★★★★★☆ |
Oriental Precision & EngineeringLtd | 54.53% | 3.14% | 0.80% | ★★★★★☆ |
PaperCorea | 53.09% | 1.31% | 77.27% | ★★★★★☆ |
Let's dive into some prime choices out of from the screener.
InBodyLtd (KOSDAQ:A041830)
Simply Wall St Value Rating: ★★★★★★
Overview: InBody Ltd (KOSDAQ:A041830) specializes in body composition analysis solutions globally and has a market cap of ₩335.44 billion.
Operations: InBody Ltd generates revenue primarily from its electronic medical devices and biological signal measuring devices, totaling ₩185.34 billion.
InBody Ltd. showcases robust financial health with no debt over the past five years and impressive earnings growth of 12% last year, outpacing the Medical Equipment industry’s 1.6%. Trading at a significant discount, it is valued at 72.8% below its fair value estimate. The company recently announced a share repurchase plan worth KRW 5 billion to enhance shareholder value and stabilize stock price, highlighting its strong commitment to investor returns.
- Click here to discover the nuances of InBodyLtd with our detailed analytical health report.
Examine InBodyLtd's past performance report to understand how it has performed in the past.
KG Mobility (KOSE:A003620)
Simply Wall St Value Rating: ★★★★☆☆
Overview: KG Mobility Corp. manufactures and sells automobiles and parts in South Korea and internationally, with a market cap of ₩1.20 trillion.
Operations: KG Mobility generates revenue primarily from automobile manufacturing, amounting to ₩3.63 billion.
KG Mobility has demonstrated impressive financial improvements, with its debt to equity ratio dropping from 46.7% to 22% over five years. Despite this, interest coverage by EBIT remains low at 1x. The company’s earnings skyrocketed by 1196%, significantly outpacing the auto industry average of 23%. For Q2 2024, sales reached ₩984.86 billion, slightly down from ₩1 trillion last year, while net income increased to ₩32.61 billion from ₩17.96 billion a year ago.
- Get an in-depth perspective on KG Mobility's performance by reading our health report here.
Gain insights into KG Mobility's past trends and performance with our Past report.
Boryung (KOSE:A003850)
Simply Wall St Value Rating: ★★★★★★
Overview: Boryung Corporation manufactures and sells pharmaceutical products both in South Korea and internationally, with a market cap of ₩786.92 billion.
Operations: Boryung Corporation generates revenue primarily through the sale of pharmaceutical products in both domestic and international markets. The company has a market cap of ₩786.92 billion.
Boryung has shown impressive growth, with earnings increasing by 68.7% over the past year, significantly outpacing the Pharmaceuticals industry average of 21.9%. The company's debt to equity ratio improved from 36.5% to 34.4% in five years, indicating better financial health. Recent earnings for Q2 reported sales of KRW 228.62 million and net income of KRW 23,643 million, reflecting strong performance compared to last year’s figures of KRW 80.13 million and KRW 11,318 million respectively.
- Navigate through the intricacies of Boryung with our comprehensive health report here.
Understand Boryung's track record by examining our Past report.
Key Takeaways
- Click here to access our complete index of 192 KRX Undiscovered Gems With Strong Fundamentals.
- Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
- Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Searching for a Fresh Perspective?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Boryung might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About KOSE:A003850
Boryung
Engages in the manufacture and sale of pharmaceutical products in South Korea and internationally.
Flawless balance sheet with solid track record.